Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

FORGOTTEN HISTORY: Bhvn | History Defined

Biohaven Stock Hits 52-Week Low, Cuts R&D Spending After FDA Rejection

Biohaven Ltd. (NYSE:BHVN) stock plummeted on Wednesday, reaching its 52-week low, according to data from Benzinga Pro.

Benzinga · Nov 5, 2025

Biohaven Advances Toward Potential First FDA-Approved Therapy For Spinocerebellar Ataxia, FDA Drops Advisory Meeting

Biohaven Ltd. (NYSE:BHVN) stock is trading higher on Friday following an update with respect to its New Drug Application for troriluzole for adult patients with Spinocerebellar Ataxia (SCA).

Benzinga · Aug 22, 2025

5 Dividend Growth Stocks Currently on Sale

The stock market has been experiencing wild swings since the beginning of the year on various macroeconomic and geopolitical concerns. In an environment of elevated market volatility, dividend growth stocks are considered attractive investments to ensure a steady income stream and capital appreciation. Thus, it could be wise to invest…

StockNews.com · Jun 10, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Biohaven's Neurological Disease Candidate Flunks In Late-Stage Study

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) has announced topline Phase 3 results of troriluzole in patients with spinocerebellar ataxia (SCA). The primary endpoint measured the change in the severity of symptoms among patients from the baseline to week 48 of treatment. It did not reach statistical significance in the overall SCA population as…

Benzinga · May 23, 2022

Recap: Biohaven Pharma Hldgs Q1 Earnings

Biohaven Pharma Hldgs (NYSE:BHVN) reported its Q1 earnings results on Tuesday, May 10, 2022 at 06:50 AM. Here's what investors need to know about the announcement.

Benzinga · May 10, 2022

Pfizer Acquires This Migraine Drug Maker For $11B: What Investors Need To Know

Pfizer Inc (NYSE:PFE) will acquire Biohaven Pharmaceutical Holding Company Ltd (NYSE:BHVN) for $148.50 per share, equivalent to $11.6 billion. Pfizer will also make payments at closing to settle Biohaven's third-party debt and for the redemption of all outstanding shares of Biohaven's redeemable preferred stock. The deal includes the acquisition of rimegepant (NURTEC ODT), a dual-acting…

Benzinga · May 10, 2022

Biohaven Further Deepens Its Neurology Pipeline With Bristol Myers, Knopp Biosciences Deals

Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) has

Benzinga · Feb 25, 2022

Read news from The Economist, FT, and more,
with one subscription

Coverage From

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.